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                                                                      INTRODUCTION
Validation is a subject that has grown in importance within the global healthcare industry
over the past 25 years. During that time period, it has perhaps resulted in more changes in
practices and methods.
                  One of the major concerns with any design whether it be for a facility , a piece
of equipment or a production process- is how its validation will be accomplished.
                  Validation programs must be established to facilitate the accomplishment of
that  very goal.  A clear  line of communication must be established to ensure that  the
operational objectives as implemented in the design can meet the validation requirements
for that design.1
HISTORICAL BACKGROUND:
The idea of process validation is not new and is common in many different fields of life;
one  can  find  the  need  for  process  validation  in  almost  any  kind  of  process.  Sharp
interpreted  pharmaceutical  process  validation  simply  as  a  step  in  developing  the
maintenance  of  the  quality  of  manufactured  medicines.  Process  validation  has  been
included in the first interpretations of good manufacturing practice (GMP) to ensure that
medicines are safe and have the identity and strength they are supposed to have.
US regulations. Bernard T. Loftus, a former director of FDA, previously described how
the principles of process validation evolved in the US from the first current
good manufacturing practice (cGMP) in 1963 to the first Guideline on General Principles
of Process Validation in 1987.  Prior to 1963, the only way for  FDA to prove that  a
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process had not done what it  was designed to do was to take samples from the final
product, analyse them and show deviations from the specification.
                          From 1963, the law stated that a pharmaceutical manufacturer had to
follow cGMP regulations whilst FDA received authorization to inspect  manufacturing
facilities. This was a direct consequence of a series of accidents in which people were
injured and even killed.
These incidents led to the evaluation of manufacturing processes, but it still took a long
time before the authorities could point out clear and serious production faults and demand
better procedures and processes.
Things  began  to  change  during  the  late  1960s  and  early  1970s  when  new types  of
incidents,  such  as  poorly  mixed,  highly  potent  tablets  and  insufficient  sterilization
procedures for large volume parenterals caused serious patient disorders. Many speeches
pointing  out  the  need  for  process  validation  were  made  by  US  authorities  and  the
expression "validated manufacturing process" was finally defined in the Drug Process
Inspections Compliance Program in 1978. The more precise definition and adjustment of
the concept for process validation was published in the Guideline on General Principles
of Process Validation in 1987 and, since then, exhaustive process inspections have been
routinely performed by FDA. It took a long time before process validation was directly
named in US cGMP regulations.2 
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                                   On march 29, 1983 draft on guidelines entitled “Guidelines on General 
principles of process validation” was made available & the same was finalized in may 
1987 3 
The finalized definition was as follows “A documented programme, which provides a 
high degree of assurance that a specific process will consistently produce a product 
meeting its predetermined specifications & quality attributes. 3,4
New definition of process validation as "the collection and evaluation of data, from the
process  design  stage  through  production,  which  establishes  scientific  evidence  that  a
process is capable of consistently delivering quality products". Thus, process validation is
now split up into 3 stages shown in figure 1:
• Stage  1  "Process  Design"  (The  commercial  process  is  based  on  experiences
gained from development and scale-up)
• Stage 2 "Process Qualification" (During this stage, the reproducible, commercial
scale is confirmed on the basis of process design)
• Stage 3 "Continued Process Verification" (This stage is meant to show that the
process is in a state of control during routine production)
The text states expressly that in practice these 3 stages might overlap. With emphasis, it
urges manufacturers to prove with a high degree of assurance that the product can be
manufactured according to the quality attributes before a batch is placed on the market.
For this purpose,  data from laboratory-, scale-up and industrial  scale are meant to be
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used. The data are explicitly meant to cover conditions involving a great risk of process
variation.
Figure 1:  Three stage model of process validation according to FDA Guidance for
Industry – Process Validation
              FDA Guidance for Industry – Process Validation: General Principles and
Practices describes process validation as an integral part of a product's entire life cycle.
For  this  purpose  the  familiar  concepts  of  the  current  ICH  Guidelines  Q8  (R2)
Pharmaceutical  Development,  Q9 Quality  Risk Management  and Q10 Pharmaceutical
Quality System are embraced and applied to the topic of process validation:
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              Validation is an integral part of the quality assurance and its simple meaning is 
‘action of proving’. It involves controlling the critical steps of a system, which results in 
output of repeatable attributes validation itself does not improve the process but confirms 
consistent output. 6
TYPES OF VALIDATION:
Following are the different types of validation.
∗ Process validation
∗ Analytical method validation
∗ Cleaning validation
∗ Water system validation
∗ Computer system validation
∗ Equipment qualification
∗ Facility qualification
 Qualification is the subset of validation. Qualification and validation only appear 
to be the beginning of a continues development process in the quality assurance of
the pharmaceutical industry. Equipment or equipment systems are qualified & 
processes are validated.
WHY VALIDATION:
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The prime objective of the pharmaceutical plant, whether in production or in quality 
control is to manufacture consistently products of the requisite quality at the lowest 
possible cost. 
                 According to FDA, assurance of product quality is derived from careful and
systematic  attention  to  a  number  of  important  factors,  including  selection  of  quality
components  and  materials,  adequate  product  and  process  design  and  control  of  the
process through in-process and end-product testing.
                    Thus, it is through careful design (qualification) and validation of both the
process and its control systems that a high degree of confidence can be established that
all the individual manufacturing units of a given batch or succession of batches that meet
specifications will be acceptable.
GMPs and validation, two concepts that cannot be separated are essentially to quality 
assurance. Frequently, the validation of a process will lead to quality improvement, in 
addition to better quality consistency. 
The reasons why pharmaceutical industry is concerned that their process performs 
consistently as expected that is, they are validated. 6,12
Assurance of quality:
It is important for the well understanding that, the process is in a state of control and to get
confidence in the quality of the product manufactured.
Cost reduction:
 Experience  and  common  sense  indicates  that  a  validated  process  is  a  more  efficient
process and a process that possesses less re-works, rejects, wastages and so on.
Regulatory requirement:
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Validation is  considered  to be an integral  part  of  GMPs. Worldwide compliance  with
validation  requirements  is  necessary  for  obtaining  approval  to  manufacture  and  to
introduce new products.
Process optimization:
The  optimization  of  a  process  for  maximum  efficiency,  while  maintaining  quality
standards  is  a  consequence  of  validation.  The  optimization of  the  facility,  equipment,
systems and processes results in a product that meets quality requirements at the lowest
cost.
PRINCIPLES OF VALIDATION:
  The basic principles for validation was stated as follows
Quality, safety and effectiveness must be designed and built into the product.
Establish  that  the  process  equipment  has  the  capability  of  operating  within  required
parameters.
Demonstrate  that  controlling,  monitoring  and/or  measuring  equipment  and
instrumentation are capable of operating within the parameters prescribed for the
process equipment.
Perform replicate cycles (runs) representing the required operational range of the
equipment to demonstrate that the processes have been opted within the prescribed
parameters for the process and that the output or product consistently meets the
predetermined specifications for quality
Monitor the validated process during routine operation. As needed, re-qualify and
rectify the equipment.
Once the process has been completely defined, equipment usually will be required
to  perform  the  actual  processing  of  the  product.  It  is  collectively  called  “the
system”. The system and its operations can then be identified and defined.8
BENEFITS:
 Reduces the risk of regulatory non- compliance.
 Reduction in rejections & reworks.
 Reduces the chances of product recall from the market
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 Reduction of quality costs namely 
 Preventive costs
 Appraisal costs
 Internal failure costs
 External failure costs
 May require less in-process control and end product testing; parametric release of 
batch can be done.
 More rapid & accurate investigations into process deviations.
 Assures smooth running of process.
REGULATORY BASIS OF VALIDATION:
The pre-requisites of validation are embodied with in the scope of existing cGMP 
regulations. According to USFDA current good manufacturing practices (cGMP) 
 21 CFR 211.110: control procedures shall be validate performance of the 
manufacturing processes that may be responsible for causing variability in the 
characteristics of in-process material and the drug product.
 211.68- validation of computerized or automated processes
 211.84(d)(2)- validation of supplier’s test results for components when these 
test results are accepted inlieu of in-house testing after receipt.
 211084(d)(3)- validation of supplier’s test results containers and closures 
when these test results are accepted inlieu of in-house testing after receipt.
 211.110(a)- validation of manufacturing processes to ensure batch uniformity 
and integrity of drug products.
 211.113(b)- validation of sterilization processes.
 211.165(e)- validation of analytical methodologies (explicity defines 
validation)
                          The principles and guidelines of GMP for EU were published 
in directive 2003/94/EC for human drugs. 6
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PROCESS VALIDATION:
It has been said that there is no specific basis for requiring a separate set of process 
validation guidelines, since the essentials of process validation are embodied with in the 
purpose and scope of the present cGMP regulations. The specific term process 
validation should be reserved for the final stages of the product/ process development 
sequence. 7 The schematic picture of process validation for a new/existing process/ 
product is shown in figure 3.
              Validation master plan:
              Validation master plan may be defined as internally approved document that describes in
clear, unambiguous and concise wording, the general expectations, inventions, methods 
and approaches to be used during the entire validation effort.3,11
      The ECE guide recommends the following contents in VMP
 Validation policy
 Organizational structure of validation activities
 Summary of facilities, systems, equipment and processes to be validated
 Documentation format (format to be used for protocols & reports)
 Planning & scheduling
 Change control
 Reference to existing documents. 4
  
Validation protocol:
After preparing VMP, the next step is to prepare validation protocol. There are atleast the
following contents in a validation protocol.
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 Purpose and scope of validation
 Responsibilities & functioning of persons/organizational units involved in 
validation
 Type of validation to be conducted
 Number of process validation runs
 Quality of materials used in the process
 Description of process
 All major equipments to be used, their type/design and their installation & 
operational qualification
 Critical process parameters & operating ranges
 Sampling plans
 Specifications & test data to be collected
 Acceptance criteria to include that validation has been successful
 Measures to be taken in the event of process validation failure.4
                           Validation protocols define the extent of verification, testing & 
challenging activities along with their appropriate acceptance criteria, testing methods 
& data recording methods. The validation program and its protocols are generally 
divided into the following 4 phases.
 Design qualification (DQ) protocol:
This document generally provide the means to verify that the proper process
functional requirements have been incorporated into the basis for design for all
engineered systems and are included as part of performance criteria for system
hardware and software.
 Installation qualification (IQ) protocol:
This  document  provides  basis  for  verifying  the  proper  installation  of  the
designed system, in accordance with the design & engineering specifications.
 Operational qualification (OQ) protocol:
This document provides basis for testing the components of a installed system
to demonstrate conformance with the approved operational criteria.
 Performance qualification (PQ) protocol:
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This document provides basis for challenging the proper performance of the
whole-total system while operating as an integral part of the process.
Validation report:
A  written  report  should  be  available  after  completion  of  the  validation.  If  found
acceptable,  it  should  be  approved  and  authorized.  The  report  should  include  the
following
• Title and objective of the study
• References to protocols
• Details of materials 
• Equipment 
• Programme and cycles used
• Details of procedures and tested methods
• Results (compared with acceptance criteria), and
• Recommendation on the limit and criteria to be applied on future basis.
RESPONSIBILITIES OF EACH ORGANIZATIONAL STRUCTURE:
Department                                                        Responsibility 
Engineering                                              Installation qualification & certification of plant,
                                                                  facilities, equipment & support system.
Development                                             Design, optimization & qualification of   
                                                                   manufacturing process with in design limits,  
                                                                   specifications and/or requirement
Manufacturing                                          Operation & maintenance of plant, facilities, 
11
                                                                  equipment, support system & specific
                                                                  manufacturing process with in design limits,  
                                                                  specifications and/or requirements.
Quality Assurance                                   Establishment of approvable validation protocols
                                                                 & conducting  process validation by  monitoring,
                                                               sampling, testing, challenging and/or auditing 
                                                             specific manufacturing process for compliance with
                                                               design limits, specifications and/or requirements. 6
VALIDATION LIFE CYCLE:
process  validation  life  cycle  starts  at  the  process  design  phase  (process/product
development) and continues through process verification (monitoring & assessment of
process effectiveness) as stated by FDA’s new guideline on process validation activities
are carried out. Validation life cycle is shown in figure 2. 6,9
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          Fig:3 validation process of new and existing product/process10
WHAT SHOULD BE VALIDATED?
Any aspect of operation, including significant changes to premises.  Facilities, equipment
or processes, which may affect the quality of the product directly or indirectly should be
qualified and validated.
Laboratory scale batches:
These are produced at the research & early development laboratory stage; they may be of
very small size. These batches may find many uses, for example to support formulation &
packaging development, clinical and/or pre-clinical studies.
Data derived from these batches assist in the evaluation & definition of critical product
performance characteristics and there by enables the choice of appropriate manufacturing
process.
Pilot batches:
These may be used in the process development or optimization stage,  may be used to
support  formal  stability studies  and also to support  pre-clinical  & clinical  evaluation.
Pilot batch size should correspond to atleast 10% of the production scale batch i.e such
that the multiplication factor for scale-up does not exceed 10.
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Ongoing process
evaluation
For oral solid dosage forms this size should generally be 10% of the production scale or
1,00,000 units which ever is greater. The role of pilot scale batches is to provide data
predictive of  the production scale product.  It  may be necessary to further  develop &
optimize the manufacturing process using pilot scale batches. The pilot batch therefore
provides the link between process development and industrial production of product. The
purpose of the pilot batch is to challenge the method proposed for routine production i.e
to analyze and evaluate the difficulties and critical points of manufacturing process, the
apparatus and method most appropriate to large scale production.
Production scale batches:
These batches are of the size which will be produced during the routine marketing of the
product. Data on production scale batches may not always be available prior to granting
marketing authorization. Where production scale data are not available or presented at the
time of submission, the two stage approach outlined below should be followed.
First  a  thorough  evaluation  &  characterization  of  the  critical  process  parameters  at
laboratory or pilot scale, followed by a formal validation programme on production scale
batches  for  which the scheme has been  described  to  the regulatory authorities  in  the
dossier and for which the results can be subsequently verified by supervising authority
according to national procedure.
PROCESS VALIDATION PHASES:
Phase 1 (process capability design):
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FDA in its process validation guidelines states that a manufacturer should evaluate all
factors that affect product quality when designing and undertaking a process validation
study.
Process capability is the carrying out of studies to determine 6
• The number & relative importance of critical process parameters that influence
process output
• The numerical values or ranges for each of the critical process parameters that
result in acceptable process output.
If  the process  capability is  properly  defined,  the process  should result  into output  of
consistent  attributes  when  operated  with  in  the  defined  limits  of  critical  process
parameters.
Phase 2 (process validation phase or process qualification phase):
It is designed to verify that all established limits of the critical process parameters are
valid and that satisfactory products can be produced even under worst case conditions. It
represents the actual studies or trials conducted to show
• That  all  systems,  sub-systems  or  unit  operations  of  a  manufacturing  process
perform as intended
• That all critical parameters operate with in their assigned control limits
• That such studies & trials which form the basis of process capability design &
testing, are verifiable and certifiable through proper documentation.
Phase 3 (validation maintenance phase):
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It requires frequent review of all process related documents, including validation audit
reports to assure that there have been no changes, deviations, failures, modifications to
the production process and that all SOPs have been followed including change control
procedures.  At  this  stage  the  validation  team  also  assures  that  there  have  been  no
changes/deviations that should have resulted in re-qualification & re-validation.
TYPES OF PROCESS VALIDATION:
Depending  on  when  it  is  performed  in  relation  to  production,  validation  can  be
prospective, con-current, retrospective and revalidation. 6
 Prospective validation:
Prospective  validation  is  usually  undertaken  whenever  a  new  formula,  process
and/or facility need to be validated before routine pharmaceutical production starts.
It  is also usually employed when sufficient historical data is either unavailable or
insufficient  and in-process  and final  product  testing is  inadequate  to ensure  high
degree  of  confidence  for  quality  characteristics  and  reproducibility.  Regulatory
authorities  favours  prospective validation for  obvious  reason of  higher  degree  of
confidence and minimal risk, as it ensures process to be under control and effective
prior to manufacture or release of product. Nevertheless, higher degree of confidence
is also associated with higher cost of operation. Therefore, a due consideration must
be  given  to  regulatory  authority’s  preference  and  cost  to  benefit  analysis  (when
alternate type of validation is possible).
 Concurrent validation:
Concurrent validation is appropriate when
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 It  is  not  possible  to  complete  a  validation  programme  before  routine
manufacturing starts and it is known in advance that finished products will be for
sale.
 It is more appropriate to validate process during routine production due to well
understanding of process.
 Extensive testing and monitoring ensures the desired quality characteristics of
product with high degree of confidence. 
Extensive testing and monitoring during concurrent  validation may verify quality
attributes of  the product of particular batch, but does not provide high degree of
assurance that  subsequent  batches processes under  some condition and parameter
will attain same quality attributes. 
 Retrospective validation:
There  are  many processes  in use in  many companies  that  have  not  undergone a
formally documented validation process.  Validation of these processes is possible
provided sufficient historical data is available to provide documentary evidence that
various processes are considerably stable and are doing what they are believed to do.
         A large historical data set available may provide higher confidence and better
picture than data generated from few trail runs in prospective validation. This type of
validation  is  acceptable  only  for  well  established  processes  and  where  quality
attributes  and  critical  process  parameters  have  been  identified  and  documented.
Appropriate  in-process  specifications  and  controls  have  been  established  and
documented.  And  there  have  not  been  excessive  process  /  product  failures
attributable  to  causes  other  than operator  error  or  equipment  failure  unrelated  to
equipment suitability.
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                The number of batches to review will depend on the process but in general
data  from  5  to  10  consecutive  batches  should  be  examined  to  assess  process
consistency.  The  review  should  include  any  batches  that  failed  to  meet
specifications. However any discrepancies or failure in the historical data may be
excluded provided there is sufficient evidence that the failure was caused by isolated
occurrences.
                The source of this validation may include batch documents, control charts,
maintenance  log books,  records  of  personnel  changes,  process  capability  studies,
finished product data including trend cards and storage stability studies. 
 Revalidation:
Re-validation is needed to ensure that the changes in the process and/or in the 
process environment, whether intentional or unintentional, do not adversely affect 
process characteristics and product quality.
Re-validation may be divided in to two broad categories:
 Re-validation after any change having a bearing on product quality.
 Periodic re-validation carried out at scheduled intervals.
Revalidation after changes:
Revalidation must be performed on introduction of any changes affecting a 
manufacturing and/or standard procedure having a bearing on the established 
product performance characteristics. Such changes may include those in starting 
materials, packaging materials, manufacturing process, equipment, in-process 
controls, manufacturing area or support systems (water, steam etc). Every such 
change requested should be reviewed by a qualified validation group which will 
decide whether it is significant enough to justify revalidation and if so, its extent.
                  Re-validation after changes may be based on the performance of the same
tests and activities as those used during the original validation including tests on sub 
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processes and on the equipment concerned. Some typical changes which require 
revalidation include the following
∗ Changes in the starting materials:
Changes  in  the  physical  properties  such  as  density,  viscosity,  particle  size
distribution,  crystal  type  and  modification of  the  active ingredients  or  excipients
may effect  the mechanical  properties of the material, as a concequence they may
adversely affect the process or the product.
∗ Changes in the packaging material:
Example replacing plastics by glass may require changes in the packaging procedure
and therefore effect the product stability.
∗ Changes in the process:
Changes in the mixing time, drying temperature and cooling regime may effect
subsequent process steps and product quality.
∗ Changes in equipment:
Measuring  instrument  may  effect  both  the  process  and  the  product.  Repair  and
maintenance work such as replacement of major equipment components may effect
the process.
∗ Changes in the production area and support system:
The  rearrangement  of  manufacturing  area  and/or  support  systems  may  result  in
changes  in  the  process.  The  repair  and  maintenance  of  support  systems  such  as
ventilation  may  change  the  environmental  conditions  and  as  a  consequence
revalidation/requalification may be necessary mainly in the manufacture of sterile
products.
Periodic revalidation:
It  is  well  known  that  process  changes  may  occur  gradually  even  if  experienced
operators work correctly according to established methods. Similarly equipment wear
may  also  cause  gradual  changes.  Consequently  revalidation  at  scheduled  times  is
advisable even if no changes have been deliberately made.
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             The decision to introduce periodic revalidation should be based on a review of
historical data i.e data generated during in-process and finished product testing after
the latest validation, aimed at verifying that the process is under control.
2. LITERATURE REVIEW
Chawla Nirmaljot singh et-al 13 ; has overviewed role of process validation of 
tablet manufacturing process. It often includes qualification of systems & 
equipment. For each type of pharmaceutical dosage form there are various stages 
in manufacturing process that need to be qualified inoder to validate the complete 
process. 
Rajkumar P.Patil  14;  has explored the understanding of blend uniformity in the
manufacture of solid oral dosage forms under c GMP. He concluded that testing
final blend uniformity as a suitable in-process control may evaluate and highlight
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the  incoming  ingredient  batch  to  batch  differences  as  well  as  the  physical
variations in different lots of active materials.
Wayne  A.Taylor  15 ;  described  the  application  of  many  statistical  tools  like
control charts, capability studies, designed experiments, tolerance analysis, robust
design  methods,  failure  mode  and  effect  analysis,  sampling  plans,  mistake
proofing  in validation.
Satyabrata Jena et-al 16; have done overview on the process validation of solid
dosage  forms,  protocol  preparation  and regulatory basis  for  process  validation
with special emphasis on tablets in industry.  It  gives in detail the validation of
each step of the manufacturing process through wet granulation. They concluded
that Solid dosage form validation should be part of a comprehensive validation
program within an industry. The total program should begin with validation of the
active pharmaceutical ingredient (API) characteristics so that this material will be
uniform batch after batch, providing a solid footing upon which the dosage form
will  be  built. Continued  awareness  of  validation  requirements  and  a  diligent
application of validation principles will thus help to ensure that pharmaceutical
products  will  be  able  to  be  developed  and  produced  with  the  quality  and
reproducibility required from regulatory agencies across the world.
Garg R et-al  17;  has described guidance for validation of solid dosage forms,
sterile  products,  oral  solutions  and  suspensions.  They  gave  an  overview  on
aspects of validation in terms of pharmaceutical unit operations, i.e that individual
technical operation that comprises various steps involved in product design and
evaluation.
Beer  TR  et-al  18;  studied  a  strategy  to  implement  a  Process  Analytical
Technology  (PAT)  system  in  the  blending  step  of  tablet  production  system.
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Raman spectroscopy was used as a PAT tool for end point control of powder
blending process. It was observed that the ratio between the blending times and
the measurement  intervals  should  be  sufficiently  high  to  be  able  to  study the
critical effects properly.
Chitlange S et-al  19;  provided information on validation of granulation process
which involved validation of equipments utilized in manufacturing of granulation
and  validation  of  operation  carried  out  for  granulation.  It  also  validate  final
product  for  bulk  density,  moisture  content,  particle  size  distribution  etc.
successfully  validating  a  process  may  reduce  the  dependence  upon  intensive
inprocess and finished product testing.
Elsie Jatto et.al 20; have done overview of pharmaceutical validation and process
controls  in  drug development.  It  has  been  known that  facilities  and processes
involved in pharmaceutical production impact significantly on the quality of the
products. The processes include raw material and equipment inspections as well
as in-process controls. Process controls are mandatory in GMP. The purpose is to
monitor the on-line and off-line performance of the manufacturing process and
hence, validate it. Thus validation is an integral  part of quality assurance. This
overview  examines  the  need  for  pharmaceutical  validation,  the  various
approaches and steps involved and other pertinent considerations.
 Andrew W. Jones  21 discussed how to validate a process by introducing some
basic  statistical  concepts  to  use  when  analyzing  historical  data  from  Batch
Records and Quality Control Release documents to establish specifications and
quality attributes for an existing process.
Dusel-RG  et-al  22;  performed  food  and  drug  administration  requirements
regarding manufacturing process validation were discussed including examples of
24
different  types  of  documentation  to  fulfill  the  requirements  of  minimal  or
extensive records.
O’-shea-et-al  23;  have  done  an  overview  of  validation  in  the  pharmaceutical
industry including legal, ethical, developmental & economic considerations and
also included validation process for granulating, blending and tableting a product.
Edwards-CM et al 24; have done process validation of the manufacturing of solid
dosage  forms  was  discussed  including  protocols,  records  to  be  maintained,
suitability of raw materials, equipment performance qualification, the number of
validation runs required and acceptance criteria.
                                        3. AIM & OBJECTIVE OF STUDY
 The  present  study  is  carried  out  at  Orchid  Healthcare,  Irrungattukottai.  The
company  is  involved  in  the  manufacturing  and  distribution  of  wide  range  of
pharmaceutical products. 
 The  aim  of  the  present  work  is  to  define  the  validation  process  for  an  Anti
convulsant  tablet  750mg and  to  manufacture  3  validation  batches  of  3,00,000
tablets as per the approved batch manufacturing record.
 To evaluate and qualify the consistency of Anti convulsant tablet 750mg
 The  objective  in  process  validation  was  to  validate  critical  processes  like
granulation,  drying,  blending,  compression  &  coating  and  to  establish
documented  evidence  that  product  when  manufactured  at  production  scale
operation meets all the quality and design specifications.
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4.   PLAN OF WORK
Process validation is carried for the following product.
Anti convulsant tablet 750mg
Three consecutive batches should be manufactured for the validation of anti convulsant
tablet 750mg. 
The following plan of work is designed based on Master Manufacturing formula
1. Literature review
2. Preparing process flow chart
3. Preparing the validation protocol which include
• Review of qualification status of equipment & facility
• Identification of CCPs & CQAs
• Preparation of sampling plan 
• Acceptance criteria
4. Execution of validation
5. Compilation & evaluation of the results.
5. DRUG PROFILE
The present drug of study is an anti convulsant tablet 
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Description:
This anti convulsant drug is a white to off-white crystalline powder with a faint odor and
a bitter taste. 
Solubility:
 It is very soluble in water (104.0 g/100 mL). 
 It is freely soluble in chloroform (65.3 g/100 mL) & in methanol (53.6 g/100 mL)
 soluble in ethanol (16.5 g/100 mL)
  sparingly soluble in acetonitrile (5.7 g/100 mL).
  practically insoluble in n-hexane. 
(Solubility limits are expressed as g/100 mL solvent.)
Indications and usage:
 indicated as adjunctive therapy in the treatment of partial  onset seizures in
adults and children 1 month of age and older with epilepsy.
  indicated  as  adjunctive  therapy  in  the  treatment  of  myoclonic  seizures  in
adults  and adolescents  12 years  of  age  and older  with  juvenile  myoclonic
epilepsy.
 indicated as adjunctive therapy in the treatment of primary generalized tonic-
clonic seizures in adults and children 6 years of age and older with idiopathic
generalized epilepsy.
Available strengths:
The present drug of study is available in 250mg, 500mg, 750mg & 1000mg strengths.
Mechanism of action:
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Mechanism  unknown;  may  selectively  prevent  hypersynchronization  of  epileptiform
burst firing and propagation of seizure activity ; thought to stimulate synaptic  vesicle
protein 2A (SV2A), inhibiting neurotransmitter release.
Pharmacokinetics
Absorption
T max  is 1 h. Oral bioavailability is 100%. Food does not affect the extent of absorption,
but it can decrease C max 20% and delay T max 1.5 h. Steady state is achieved after 2 days
of multiple, twice-daily dosing.
Distribution
Less  than  10%  is  protein  bound.  Vd  is  close  to  the  volume  of  intracellular  and
extracellular water.
Metabolism
Not extensively metabolized. Major metabolic pathway is the enzymatic hydrolysis of the
acetamide group, which produces the carboxylic acid metabolite ucb L057.
Elimination
Plasma half-life is approximately 7 h. It  is eliminated from the systemic circulation by
renal excretion as unchanged drug, which represents 66% of dose.
Drug interactions:
Carbamazepine
Increased risk of carbamazepine toxicity,  unrelated to elevated plasma concentrations,
has been reported.
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Probenecid
The  C max of  the  inactive  metabolite  of  this  anti  convulsant  drug  is  approximately
doubled.
Adverse reactions:
The  most  common  adverse  effects  occurring  with  this  drug  were  CNS  related  and
included  somnolence,  asthenia,  and  dizziness.The  frequency  of  these  symptoms  was
higher in patients started on higher dosages (> 1000 mg/day)
Process
stage
Process
variable
samples Testing
neededNo. of 
samples 
to be 
taken
Type of 
containers
Sample 
size
No. of 
samples 
to be 
tested
Drying Dried granules
of batch at an 
inlet 
temperature of
60 ±5 ºC for 
10 min in 
FBD till the 
1 pooled 
sample
If LOD 
is 1.5 – 
3.0%
Glass vial 1 gm at 
each 
location
1 pooled 
sample 
for every
10 min 
till LOD 
shall be 
1.5-3% 
w/w
LOD
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LOD shall be 
1.5 – 3%
5 
samples
If LOD 
is 1.5 – 
3.0%
1 gm at 
each 
location
5 
samples 
after 
attaining
LOD 
shall be 
1.5-3% 
w/w
Blending blend 10 
samples 
in 
duplicate
Glass vial 1050
mg to
3150mg
Die
size:5ml
10 Content 
uniformity
Blending time
Pre
lubrication:10
min
Post
lubrication:5
min
Blend rpm:15
rpm
3
samples
Poly bag Each 
100 gm
03 Bulk
density,
Particle size
distribution
After 
unloading the 
blend from 
blender in to 
SS  bin
10 
samples 
in 
duplicate
from SS 
bins
Glass vial 1050
mg to
3150mg
Die 
size:5ml
10 Content
uniformity
1 pooled 
sample 
from all 
SS bins
Poly bag 25 gm 01 Description, 
assay, water 
content
Table: 4 sampling plan
Process stage Process
variable
                    samples Testing needed
No. of samples 
to be taken
Type of 
containers
Compression 
speed
*min. set 
speed:10rpm
50 tablets Poly bags Weight of 10 tablets
Disintegration
Thickness
Weight variation
hardness
Friability
Physical inspection
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Compression
Compress about 
30,000 tablets
Pooled sample of
50 tablets from 
the containers
Poly bags Dissolution
UOD
*Max. set 
speed:18rpm
Compress about 
30,000 tablets
50 tablets Poly bags Weight of 10 tablets
Disintegration
Thickness
Weight variation
hardness
Friability
Physical inspection
Pooled sample of
50 tablets from 
the containers
Poly bags Dissolution
UOD
*Optimum 
speed:15rpm
Pooled sample of
50 tablets shall 
be collected from
corresponding 
IPC during 1/3rd 
to 2/3rd level of 
hopper
Poly bags Weight of 10 tablets
Disintegration
Thickness
Weight variation
hardness
Friability
                 Physical 
inspection
Pooled sample of
50 tablets from 
the containers
Poly bags Dissolution
                           
UOD
Table: 4 sampling plan ( contd…)
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Process stage Process
variable
                    samples Testing needed
No. of samples
to be taken
Type of 
containers
    
compression
*Optimum 
speed:15rpm
Pooled sample 
of 50 tablets 
shall be 
collected from 
corresponding 
IPC during 
2/3rd to end 
level of hopper
Poly bags Weight of 10 tablets
Disintegration
Thickness
Weight variation
hardness
Friability
                 Physical 
inspection
Pooled sample 
of 50 tablets 
from the 
containers
Poly bags Dissolution
                           UOD
         coating
Description Pooled sample Poly bags Physical appearance
Weight build up 50 tablets Poly bags Weight build up
Spary gun angle NA NA NA
Pooled sample 
of 50 tablets 
from all the 
containers
Poly bags Dissolution profile
on 12 tablets
Pooled sample 
of 250 tablets 
from all the 
containers
Poly bags Description 
Identification by
HPLC, IR, chiral
HPLC
Water content
Avg weight
Uniformity of
dosage units by wt.
variation
Dissolution 
Assay 
Related substances
*samples shall be taken from both the sides & tested atleast for two time intervals
Process stage Process
variable
                    samples Testing needed
No. of 
samples to 
be taken
Type of 
containers
   Tablet 
counting/filling
Minimum speed
Maximum speed
Target set speed
10 HDPE 
containers 
120s count
                 
Verification of fill
bottle count
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Induction sealing Induction power
supply set
05 HDPE 
container 
150cc and 
Child 
Resistant 
Closure
Visual inspection for
seal integrity
Labeling Minimum speed
Maximum speed
Target set speed
10 HDPE 
container 
150cc
Self 
adhesive 
printed 
container 
label 120s 
count
              
                 Visual 
inspection
Table: 4 sampling plan ( contd…)
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6.2.5 SAMPLING PROCEDURE AT DIFFERENT STAGES: 
 Drying:
Moisture content of the dried granules has to be established during the validation
of drying process. One pooled sample was taken for every 10min till the LOD shall
be 1.5% -3.0%. 5 samples  were  taken from 5 different  locations  in FBD after
attaining the desired LOD to determine the moisture content.
                      
                                        Fig: 6 Side View of Fluid Bed Dryer (FBD)
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                                            Fig: 7 Top View of Fluid Bed Dryer (FBD)
  Location 1 : Left side of the FBD
  Location 2 : Rear side of the FBD
  Location 3 : Right side of the FBD
  Location 4 : Front side of the FBD
  Location 5 : Center of the FBD
 Blending:
Content  uniformity of  the blend has  to  be  established during the validation of
blending process. 10 samples in duplicate were taken from different locations in
the octagonal blender and tested for the content uniformity. Sample size (1050mg-
3150mg) is average weight of each tablet to thrice of the average tablet weight. 3
samples were collected from right, middle & left sides of the octagonal blender for
determination of bulk density and particle size distribution.
Sampling in SS bins: After loading the blend in to SS bins from the blender 10 samples
in duplicate were taken to determine the content uniformity and 1 pooled sample from all
the bins was taken for description, assay and water content.
                      10 samples in duplicate (20 samples) for Content uniformity
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                                                      Fig: 8 Blender elevation view
                                                          Fig: 9 Blender top view
      
  Three samples from different locations for Bulk density & Particle size distribution
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                                                      Fig: 10 Blender elevation view
                                                             
                                                             Fig: 11Blender top view
 
  Location 1 : Left side of the Octagonal blender
  Location 2 : Middle of the Octagonal blender
  Location 3 : Right side of the Octagonal blender
                                             
 Sampling plan - SS Bin               
                     10 samples in duplicate (20 samples) for Content uniformity
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                                                           Fig: 12 Bin elevation view
                     One pooled sample for Description, Assay & Water content
         Fig: 13 Bin plain view
Compression:
Compression of 30,000 tablets each were carried out at minimum (10 rpm) and
maximum (18 rpm) speeds.50 tablets at each speed were sampled from both the
sides and tested for  physical  inspection,  weight  of 10 tablets,  weight  variation,
thickness, hardness,  friability & disintegration.  Dissolution & UOD was carried
out for pooled sample of 50 tablets from different containers. Machine speed was
optimized at 15 rpm and pooled sample of each 50 tablets were collected from the
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1 32
corresponding in-process container during 1/3rd to 2/3rd level of hopper & 2/3rd to
end level of the hopper; tested for physical inspection, weight of 10 tablets, weight
variation, thickness, hardness, friability & disintegration. Dissolution & UOD was
also carried out for pooled sample of 50 tablets from the containers.
Coating:
Coating was carried out for three lots of compressed tablets to achieve the weight
build up of 2.0%–3.0%. 50 coated tablets were sampled and tested for physical
description, weight build up. Pooled sample of 50 coated tablets were collected
from different  containers  and  dissolution profile  on 12 tablets was carried out.
Similarly  pooled  sample  of  250  tablets  were  collected  and  finished  product
analysis (description, identification, water%, average weight, uniformity of dosage
units by weight variation, dissolution, assay, related substances) was carried out.
Packing:
Tablet counting & filling:
120 tablets were counted and filled in HDPE containers 150 cc at three different
speeds; minimum (20 containers/min), maximum (40 containers/min), optimum (30
containers/min) speed. 10 containers were collected at each speed for verification of
fill bottle count.
Induction sealing:
Induction sealing of HDPE 150 cc containers with CR closures were carried out with
induction power supply was set at 70%. 5 bottles were sampled and checked for seal
integrity 
 Labeling:
Labeling  of  HDPE  containers  150cc  containing  120  tablets  were  carried  out  at
minimum  (20  containers/min),  maximum  (40  containers/min),  optimum  (30
containers/min)  speeds.  10  bottles  were  collected  at  each  speed  for  physical
inspection.
6.2.6 JUSTIFICATION FOR SAMPLING POINTS:
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Fluid bed dryer:
During the drying process hot air will be blown from the bottom and there may not be 
uniform flow of air due to which improper drying may occur. Hence samples will be 
taken at 5 different locations to check the moisture content
Octagonal blender:
Sampling points 1,2,3,4,5,6,7,8 are considered as dead spots in the octagonal blender as 
the baffle will not be in the contact with the blend at those points hence samples were 
taken to check the content uniformity. Sampling points 9, 10 are in direct contact with the
baffle hence samples were taken to check the content uniformity as over mixing may lead
to segregation of the particles.
        Three samples were taken at middle, right and left sides of the blender to check the 
bulk density & particle size distribution as there may be segregation of particles during 
mixing.
SS BIN:
After blending, blend was transferred from octagonal blender in to SS bins. During the 
transfer more denser particles may settle at the bottom of the bin and also particles may 
segregate. Hence samples were taken at various locations from the SS bins to check the 
content uniformity
Pooled samples were taken to represent all the layers of the blend and tested for 
description, assay and water content.
Duplicate samples were taken to rule out the analytical variations.
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Sample size is twice the quantity required for testing.
7. RESULTS
7.1 Stage: sifting
Visual inspection after sifting of raw materials were carried out and the results are shown 
in the table 5
Table: 5 sifting of raw materials
Test Process control Acceptance criteria Batch No.
719B001 719B002 719B003
Visual
inspection
Sifting of raw
material
Absence of any lumps
or foreign matter after
sifting of raw material
complies complies complies
7.2 Stage: Granulation
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  CCPs monitored during granulation & results of granule formation for 3 batches are 
given in   table 6
Table: 6 Results of granulation
Batch no. Dry mixing 
time(minutes)
Main motor 
amperage at 
75 rpm
Binder 
addition 
time at 100 
rpm
(minutes)
Main motor 
amperage
Granule 
formation
719B001 10 16.03 2 17.21 satisfactory
719B002 10 15.92 2 17.21 satisfactory
719B003 10 16.13 2 17.23 satisfactory
7.3 Stage: Drying
LOD at various locations are tabulated in table 7
 Table: 7 % Loss on drying
                                              LOCATIONS
Batch no. 01 02 03 04 05
719B001 2.2% 2.1% 2.15% 2.15% 2.15%
719B002 2.05% 2.2% 2.4% 2.3% 2.05%
719B003 1.9% 2.25% 2.25% 2.3% 2.05%
                                        
                                            Acceptance criteria = 1.5 to 3%
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% LOD from 3 batches is shown graphically in fig 14
                                   Figure: 14 % Loss on drying in different batches
7.4 Stage: BLENDING
7.4.1Sampling location: Octagonal blender
Results of content uniformity at various locations in the blender are given table 8 and 
it is represented graphically in fig 15
Table: 8 % Content uniformity from octagonal blender
Locations Batch no. Acceptance
criteria719B001 719B002 719B003
1. 100.2 99.2 100.6
2. 101.5 99.2 101.7
3. 100.0 98.7 101.9
4. 100.6 99.2 100.9
5. 99.9 99.2 102.2
6. 100.6 99.2 100.5
43
  NLT 90.0 % to 
NMT 110.0 % of 
the labeled 
amount.
7. 100.2 99.2 101.5
8. 99.9 98.8 100.9
9. 102.7 98.3 100.9
10. 100.2 98.1 100.1
99.9 98.1 100.1
Max. 102.7 99.2 102.2
Average 100.58 98.91 101.12
RSD 0.9 0.3             0.6 RSD: NMT 5%
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                    Figure: 15 CONTENT UNIFORMITY FROM OCTOGONAL 
BLENDER
Results of density (apparent & tapped) of blend at various locations in the blender are 
given 
table 9
Table: 9 Density of blend
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Test Sampling location: Octagonal blender (left side)
Batch no 719B001 Batch no.719B002 Batch no. 719B003
Apparent density
(g/ml)
0.59 0.57 0.59
Tapped density
(g/ml)
0.71 0.61 0.61
Test                 Sampling location: Octagonal blender (middle)
Batch no. 719B001 Batch no.719B002 Batch no. 719B003
Apparent density
(g/ml)
0.59 0.57 0.59
Tapped density
(g/ml)
0.71 0.69 0.69
Test Sampling location: Octagonal blender (right side)
Batch no. 719B001 Batch no.719B002 Batch no. 719B003
Apparent density
(g/ml)
0.59 0.57 0.59
Tapped density
(g/ml)
0.71 0.69 0.69
Results of particle size distribution of blend at various locations in the blender are given 
table 10, 11, 12 and are represented graphically in fig 17, 18, 19 respectively.
Table: 10 particle size distribution of blend from left side of the blender
Sampling location: Octagonal blender (left side)
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Sieve ID no. % of material retained on ASTM sieve
Batch no. 719B001 Batch no. 719B002 Batch no. 719B003
#20 5.30 6.35 6.24
#30 11.59 13.44 13.79
#40 15.89 18.94 19.18
#60 22.94 26.44 26.57
#80 28.59 33.48 33.27
#100 36.38 39.49 39.46
#200 53.02 54.07 54.15
Cumulative material
collected 99.50 99.90 99.70
Table: 11 particle size distribution of blend from middle of the blender
Sampling location: Octagonal blender (middle)
Sieve ID no. % of material retained on ASTM sieve
Batch no. 719B001 Batch no. 719B002 Batch no. 719B003
#20 5.50 5.69 6.35
#30 12.39 13.04 13.59
#40 17.09 17.53 19.19
#60 23.79 25.02 26.54
#80 29.54 32.67 33.83
#100 36.03 38.51 40.18
#200 52.32 53.40 54.77
Cumulative material
collected
99.55 99.50 99.65
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                   Fig: 17 PARTICLE SIZE DISTRIBUTION FROM LEFT SIDE OF 
BLENDER
                       Fig: 18 PARTICLE SIZE DISTRIBUTION FROM MIDDLE OF 
BLENDER
Table: 12 particle size distribution of blend from right side of the blender 
Sampling location: Octagonal blender (right side)
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Sieve ID no. % of material retained on ASTM sieve
Batch no. 719B001 Batch no. 719B002 Batch no. 719B003
#20 5.35 5.80 6.35
#30 11.95 13.14 13.59
#40 16.20 17.64 19.19
#60 23.40 25.29 26.54
#80 28.25 32.78 33.83
#100 35.25 38.28 40.8
#200 51.80 53.07 54.77
Cumulative material
collected
99.75 99.70 99.65
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                Fig: 19 PARTICLE SIZE DISTRIBUTION FROM RIGHT SIDE OF 
BLENDER
 Stage: BLENDING
7.4.2 Sampling location: SS bin
Results of pooled sample of blend from SS bin are shown in table 13
 Table: 13 Description, %water content & assay of pooled sample of blend from SS bin
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           Test       Acceptance criteria                        Batch No.
719B001 719B002 719B003
Description White to off white granular 
powder
White 
granular 
powder
White 
granular 
powder
White 
granular 
powder
Water content by 
KF (%w/w)
              NMT 3% 2.0% 1.6% 2.0%
Assay Tablet blend contains the 
equivalent of NLT 95% and 
NMT 105% of the labeled 
amount
98.9% 99.6% 99.3%
Stage: BLENDING
Sampling location: SS bin
Results of content uniformity of blend from SS bin are tabulated in table 14 & shown 
graphically in fig 16
Table: 14 % Content uniformity of blend from SS bin
Locations Batch no. Acceptance
criteria719B001 719B002 719B003
1. 100.2 99.4 100.6
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 NLT 90.0 % to 
NMT 110.0 % of 
the labeled 
amount.
2. 99.9 99.3 100.9
3. 103.0 99.0 101.5
4. 101.0 99.1 101.3
5. 101.1 100.4 100.6
6. 100.9 99.7 100.0
7. 100.1 98.8 100.9
8. 100.5 99.0 100.9
9. 100.4 99.3 99.1
10. 100.2 99.8 101.3
99.9 98.8 99.1
Max. 103.0 100.4 101.5
Average 100.73 99.38 100.71
RSD 0.9 0.5 0.7 RSD: NMT 5%
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                                        FIG: 16 CONTENT UNIFORMITY FROM SS BIN
7.5 Stage: COMPRESSION
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Weight of 10 tablets from each validation batch at three different speeds are given in 
table 15
Table: 15 Weight of 10 tablets from each batch at minimum, maximum & optimum speeds.
Batch No. Process 
variable
Acceptance criteria                Sample No./Description
Left Right
719B001 Compression 
machine at 
minimum 
speed (10rpm)
Min:10.29g
Target:10.50g
Max:10.71g
10.55 10.53
719B002 10.79-10.54 10.53-10.57
719B003 10.52-10.53 10.52-10.54
719B001 Compression 
machine at 
maximum 
speed (18rpm)
10.50-10.51 10.49-10.52
719B002 10.50-10.53 10.50-10.52
719B003 10.54 10.53
719B001 Compression 
machine at 
optimum 
speed (15rpm)
First half 
stage
10.49-10.59 10.51-10.62
719B002 10.50-10.60 10.49-10.60
719B003 10.49-10.54 10.52-10.54
719B001 Compression 
machine at 
optimum 
speed (15rpm)
second half 
stage
10.52-10.54 10.50-10.52
719B002 10.51-10.56 10.49-10.55
719B003 10.49-10.54 10.49-10.54
Stage: COMPRESSION
Disintegration time of sampled tablets from each validation batch at three different 
speeds are given in table 16
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Table: 16 Disintegration time of tablets from each batch at minimum, maximum & optimum 
speeds
Batch No. Process 
variable
Acceptance criteria                Sample No./Description
Left Right
719B001 Compression 
machine at 
minimum 
speed (10rpm)
    NMT 15 minutes
06 min 15 sec     06 min 20 sec
719B002 06 min 05 sec 06 min 07 sec
719B003 06 min 10 sec 06 min 08 sec
719B001 Compression 
machine at 
maximum 
speed (18rpm)
06 min 21 sec 06 min 18 sec
719B002 06 min 05 sec 06 min 10 sec
719B003 06 min 32 sec 06 min 22 sec
719B001 Compression 
machine at 
optimum 
speed (15rpm)
First half 
stage
06 min 22 sec 06 min 21 sec
719B002 06 min 05 sec 06 min 10 sec
719B003 06 min 18 sec 06 min 11 sec
719B001 Compression 
machine at 
optimum 
speed (15rpm)
second half 
stage
06 min 25 sec 06 min 19 sec
719B002 06 min 12 sec 06 min 10 sec
719B003 06 min 10 sec 06 min 02 sec
Stage: COMPRESSION
Thickness of sampled tablets from each validation batch at three different speeds are 
given in table 17
Table: 17 Thickness of tablets from each batch at minimum, maximum & optimum speeds
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Batch No. Process 
variable
Acceptance criteria                Sample No./Description
Left Right
719B001 Compression 
machine at 
minimum 
speed (10rpm)
Min: 6.3 mm
Max: 6.9mm
6.6 - 6.8 6.6 - 6.7
719B002 6.5 - 6.8 6.5 - 6.8
719B003 6.6 - 6.7 6.5 - 6.7
719B001 Compression 
machine at 
maximum 
speed (18rpm)
6.5 – 6.7 6.6 – 6.8
719B002 6.5 – 6.7 6.6 – 6.7
719B003 6.5 – 6.7 6.6 – 6.7
719B001 Compression 
machine at 
optimum 
speed (15rpm)
First half 
stage
6.4 – 6.8 6.5 – 6.7
719B002 6.5 – 6.7 6.5 – 6.7
719B003 6.5 – 6.8 6.5 – 6.7
719B001 Compression 
machine at 
optimum 
speed (15rpm)
second half 
stage
6.5 – 6.7 6.5 – 6.7
719B002 6.5 – 6.6 6.5 – 6.6
719B003 6.5 – 6.7 6.5 – 6.6
Stage: COMPRESSION
Weight variation of sampled tablets from each validation batch at three different speeds 
are given in table 18
Table: 18 Weight variation of tablets from each batch at minimum, maximum & optimum 
speeds
Batch No. Acceptance criteria                Sample No./Description
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Process 
variable
Left Right
719B001 Compression 
machine at 
minimum 
speed (10rpm)
      
Min:998mg
Target: 1050mg
Max: 1102 mg
1032 - 1073      1034 – 1071
719B002 1036 - 1064 1033 - 1066
719B003 1035 - 1077 1035 - 1077
719B001 Compression 
machine at 
maximum 
speed(18 rpm)
1029 - 1078 1028 - 1064
719B002 1024 - 1063 1037 - 1069
719B003 1041 - 1042 1037 - 1064
719B001 Compression 
machine at 
optimum 
speed (15rpm)
First half 
stage
1030 - 1075 1031 - 1075
719B002 1034 - 1072 1035 - 1068
719B003 1035 - 1081 1041 - 1068
719B001 Compression 
machine at 
optimum 
speed (15rpm)
second half 
stage
1032 - 1081      1035 - 1072
719B002 1046 - 1048 1035 - 1067
719B003 1037 - 1067 1034 - 1078
Stage: COMPRESSION
Hardness of sampled tablets from each validation batch at three different speeds are given
in table 19
Table: 19 Hardness of tablets from each batch at minimum, maximum & optimum speeds
Batch No. Process 
variable
Acceptance criteria                Sample No./Description
Left Right
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719B001 Compression 
machine at 
minimum 
speed(10 rpm)
Min:16 kp
Max: 25 kp
16 – 23 18 - 25
719B002 18 - 23 17 - 23
719B003 19 - 24 18 - 23
719B001 Compression 
machine at 
maximum 
speed (18rpm)
17 - 24 17 - 24
719B002 17 - 22 17 - 24
719B003 17 - 20 20 - 23
719B001 Compression 
machine at 
optimum 
speed (15rpm)
First half 
stage
17 - 25 19 - 25
719B002 17 - 21 17 - 24
719B003 19 - 24 20 - 24
719B001 Compression 
machine at 
optimum 
speed (15rpm)
second half 
stage
19 – 25 19 - 25
719B002 17 - 23 17 - 25
719B003 20 - 24 18 - 23
Stage: COMPRESSION
Physical inspection of sampled tablets from each validation batch at three different 
speeds are given in table 20
Table: 20 Physical inspection of tablets from each batch at minimum, maximum & optimum 
speeds
Batch No. Acceptance criteria                Sample No./Description
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Process 
variable
Left Right
719B001 Compression 
machine at 
minimum 
speed(10 rpm)
      
Free from physical 
defects
complies complies
719B002 complies complies
719B003 complies complies
719B001 Compression 
machine at 
maximum 
speed (18rpm)
complies complies
719B002 complies complies
719B003 complies complies
719B001 Compression 
machine at 
optimum 
speed (15rpm)
First half 
stage
complies complies
719B002 complies complies
719B003 complies complies
719B001 Compression 
machine at 
optimum 
speed (15rpm)
second half 
stage
complies complies
719B002 complies complies
719B003 complies complies
Stage: COMPRESSION
Friability of sampled tablets from each validation batch at three different speeds are given
in table 21
Table: 21 Friability of tablets from each batch at minimum, maximum & optimum speeds
Batch No. Process 
variable
Acceptance criteria                Sample No./Description
Left Right
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719B001 Compression 
machine at 
minimum 
speed(10 rpm)
      
NMT 1%
0.2 – 0.3 % 0.3 %
719B002 0.2 – 0.3 % 0.2 %
719B003 0.2 % 0.2 %
719B001 Compression 
machine at 
maximum 
speed (18rpm)
0.3 % 0.2 – 0.3 %
719B002 0.2 – 0.3 % 0.2 %
719B003 0.2 % 0.2 %
719B001 Compression 
machine at 
optimum 
speed (15rpm)
First half 
stage
0.2 – 0.3 % 0.2 %
719B002 0.3 % 0.2 – 0.3 %
719B003 0.2 – 0.3 % 0.2 – 0.3 %
719B001 Compression 
machine at 
optimum 
speed (15rpm)
second half 
stage
0.3 % 0.3 %
719B002 0.2 – 0.3 % 0.2 %
719B003 0.3 % 0.3 %
Stage: COMPRESSION
Dissolution of pooled sample of tablets from each validation batch at three different 
speeds are given in table 22 and sown graphically in fig 20.
Table: 22 Dissolution of tablets from each batch at minimum, maximum & optimum speeds
Test Process 
variable
Acceptance 
criteria
Sample 
description
Batch no.
719B001 719B002 719B003
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Dissolution
Compression
machine at 
minimum 
speed(10 
rpm)
NLT 80% 
of the 
labeled 
amount of 
anti 
convulsant 
drug 
dissolved in
15 minutes
Pooled 
sample
96%
97%
100%
99%
101%
98%
101%
98%
99%
100%
95%
101%
102%
102%
102%
101%
102%
102%
Compression
machine at 
maximum 
speed 
(18rpm)
92%
97%
100%
96%
98%
97%
101%
99%
100%
99%
100%
100%
98%
98%
100%
100%
98%
100%
Compression
machine at 
optimum 
speed 
(15rpm)
First half 
stage
96%
97%
98%
100%
100%
102%
100%
100%
97%
99%
99%
100%
99%
99%
97%
98%
94%
97%
Compression
machine at 
optimum 
speed 
(15rpm)
second half 
stage
101%
98%
92%
100%
100%
94%
100%
99%
100%
101%
99%
100%
100%
101%
98%
99%
97%
99%
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                                    Fig: 20 DISSOLUTION AT DIFFERENT SPEEDS
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Stage: COMPRESSION
Content uniformity of pooled sample of tablets from each validation batch at three 
different speeds are given in table 23 & represented graphically in fig 21.
Table: 23 Content uniformity of tablets from each batch at minimum, maximum & optimum 
speeds
Test Process variable Acceptance
criteria
Sample
descrip
tion
Batch no.
719B001 719B002 719B003
Uniformit
y of 
dosage 
units by 
content 
uniformity
Compression 
machine at 
minimum 
speed(10 rpm)
Acceptance
value 
should be <
L1% (15.0)
Pooled
sample
0.7 1.5 1.7
Compression 
machine at 
maximum speed 
(18rpm)
0.7 1 1.7
Compression 
machine at 
optimum speed 
(15rpm)
First half stage
0.8 1.5 1.4
Compression 
machine at 
optimum speed 
(15rpm)
second half stage
0.8 1.2 1.5
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Fig: 21 UNIFORMITY OF DOSAGE UNITS BY CONTENT 
UNIFORMITY AT DIFFERENT SPEEDS
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7.6 Stage: COATING
Dissolution profile of pooled sample of tablets from each validation batch at different 
time intervals are given in table 24 & shown graphically in fig 22.
Table: 24 Dissolution profile on 12 tablets 
Test Process
variable
Acceptance
criteria
Sample
No./description
Batch No.
719B001 719B002 719B003
Dissolution
profile on 
12 tablets
coating
For 
reference 
purpose
05 minutes
Avg % of drug 
dissolved         
22.7 32.6 29.7
% RSD 31.9 24.5 22.3
10 minutes
Avg % of drug 
dissolved         
64.0 72.9 72.2
% RSD 16.3 12.0 14.1
15 minutes
Avg % of drug 
dissolved         
90.3 94.7 94.4
% RSD 7.5 5.4 6.1
30 minutes
Avg % of drug 
dissolved         
101.4 102.9 103.0
% RSD 0.9 0.5 1.2
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                                   Fig: 22 DISSOLUTION PROFILE ON 12 TABLETS
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Stage: COATING
Results of finished product testing of pooled sample of tablets are tabulated in table 25
Table: 25 Finished product testing
Test Specifications Batch No.
719B001 719B002 719B003
Description Blue coloured film coated 
tablets
Blue 
coloured film
coated tablets
Blue 
coloured film
coated tablets
Blue coloured 
film coated 
tablets
Identification 
a) By HPLC
The retention time of the 
major peak in the 
chromatogram of the assay 
preparation corresponds to 
that in the chromatogram of 
the standard preparation, as 
obtained in the assay
complies complies complies
b) By IR The IR spectrum of sample 
should match with that of 
standard
complies complies complies
c) By chiral 
HPLC
The retention time of the 
major peak should correspond
to the retention time of  anti 
convulsant drug peak obtained
in the chromatogram of 
standard solution
complies complies complies
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Table: 25 Finished product testing (contd…)
Test Specifications Batch No.
719B001 719B002 719B003
Water (%W/W) 
by KF
NMT 3.0 2.3 2.5 2.1
AVG weight (mg) 1076.3±3% 1080.5 1079.2 1075.7
Uniformity of 
dosage units by 
weight variation
Acceptance value
should be less than or
equal to L1%(15.0)
2.0 1.6 0.6
Dissolution NLT 80% (Q) of the
labeled amount of anti
convulsant tablet is
dissolved in 15 minutes
100%
94%
102%
102%
99%
96%
102%
102%
99%
95%
100%
93%
102%
100%
92%
99%
94%
99%
Dissolution of finished product is represented graphically in fig 23.
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                                       Fig: 23 DISSOLUTION (FINISHED PRODUCT)
Table: 25 Finished product testing (contd…)
Test Specifications Batch No.
719B001 719B002 719B003
Assay Anti convulsant tablets      101.3% 100.6% 100.4%
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contain the equivalent of 
NLT 90.0% and NMT 
110.0% of the labeled 
amount of anti convulsant 
drug
Related 
substances 
(%W/W)
Impurity A: NMT 0.2 
Impurity B: NMT 0.05
Highest unknown impurity:
NMT 0.1
Total impurities: NMT0.5
<LOQ(LOQ=
0.008)
Not detected
0.01%
0.01%
<LOQ(LOQ=
0.008)
Not detected
0.01%
0.02%
<LOQ(LOQ=
0.008)
Not detected
0.01%
0.01%
7.7 Stage: PACKING
Results of packing operations for 120’s count are given table 26
Table: 26 Results of packing 
Process
stage
Test Acceptance 
criteria
Batch No.
719B001 719B002 719B003
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Tablet 
counting & 
filling
Fill count at Min. 
speed 
20 containers/minute Shall fill 120’s 
count per each 
bottle at each 
speed
complies complies complies
Fill count at Max. 
speed 
40 containers/minute
complies complies complies
Fill count at optimum 
speed
30 containers/minute
complies complies complies
Induction 
sealing
Visual inspection foe 
seal integrity
Sealing shall be
intact
complies complies complies
Labeling 
Performance of 
labeling at Min. speed
20 containers/minute
Shall be free 
from defects
complies complies complies
Performance of 
labeling at Max. 
speed 
40 containers/minute
complies complies complies
Performance of 
labeling at optimum 
speed 
30 containers/minute
complies complies complies
8.SUMMARY AND CONCLUSION
In the present work, anti convulsant tablets were prepared by direct compression method.
All the tablets were subjected to weight variation, drug content uniformity, and hardness,
and  friability,  wetting  time,  dissolution,  drug  excipients  interaction  and  short-term
stability studies. 
Based on the above study following conclusions can be drawn : 
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• Tablets prepared by direct compression method were found to be good without
any chipping, capping and sticking.  
• The hardness of the prepared tablets was found to be in the range of 3.2 to 4.1kg/
cm2. 
• The
 
friability values were found to be in the range of 0.41 to 0.49%. 
• Disintegration time was found to be in the range of 84sec to 131sec.
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